Sudeep Kundu

2.8k total citations · 3 hit papers
18 papers, 2.1k citations indexed

About

Sudeep Kundu is a scholar working on Immunology, Physiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sudeep Kundu has authored 18 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 6 papers in Physiology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sudeep Kundu's work include Psoriasis: Treatment and Pathogenesis (8 papers), Asthma and respiratory diseases (6 papers) and Autoimmune Bullous Skin Diseases (4 papers). Sudeep Kundu is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (8 papers), Asthma and respiratory diseases (6 papers) and Autoimmune Bullous Skin Diseases (4 papers). Sudeep Kundu collaborates with scholars based in United States, Germany and Canada. Sudeep Kundu's co-authors include Brent A. Neuschwander‐Tetri, Yi Luo, Edgar D. Charles, Rose Christian, Kim Papp, Subhashis Banerjee, Diamant Thaçi, Ji Zhang, Theodore F. Reiss and Akimichi Morita and has published in prestigious journals such as New England Journal of Medicine, The Lancet and CHEST Journal.

In The Last Decade

Sudeep Kundu

17 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

2018 424 citations Arun J. Sanyal, Edgar D. Charles et al. The Lancet profile →
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

2022 219 citations April W. Armstrong, Melinda Gooderham et al. Journal of the American Academy of Dermatology profile →
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

2022 173 citations Bruce Strober, Diamant Thaçi et al. Journal of the American Academy of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sudeep Kundu United States	11	761	543	535	459	393	18	2.1k
Ryo Takahashi Japan	25	151 0.2×	413 0.8×	315 0.6×	434 0.9×	182 0.5×	106	2.1k
Roberta J. Secrest United States	16	380 0.5×	1.2k 2.2×	136 0.3×	282 0.6×	109 0.3×	27	2.5k
Shu Cao United States	23	164 0.2×	181 0.3×	209 0.4×	478 1.0×	94 0.2×	114	1.5k
F. W. Schildberg Germany	21	115 0.2×	221 0.4×	449 0.8×	712 1.6×	272 0.7×	45	2.5k
David Rubin United States	22	516 0.7×	142 0.3×	810 1.5×	416 0.9×	145 0.4×	56	1.7k
Ilaria Ruffilli Italy	27	118 0.2×	405 0.7×	237 0.4×	469 1.0×	248 0.6×	54	2.2k
Alessia Pagani Italy	22	415 0.5×	62 0.1×	205 0.4×	292 0.6×	65 0.2×	58	2.4k
Ender Terzıoğlu Türkiye	20	210 0.3×	198 0.4×	127 0.2×	359 0.8×	99 0.3×	54	1.2k
Paola Pontrelli Italy	27	132 0.2×	410 0.8×	234 0.4×	675 1.5×	170 0.4×	86	2.1k
Sylvia Stadlmann Austria	25	107 0.1×	285 0.5×	166 0.3×	610 1.3×	306 0.8×	56	2.0k

Countries citing papers authored by Sudeep Kundu

Since Specialization

Citations

This map shows the geographic impact of Sudeep Kundu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sudeep Kundu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sudeep Kundu more than expected).

Fields of papers citing papers by Sudeep Kundu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sudeep Kundu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sudeep Kundu. The network helps show where Sudeep Kundu may publish in the future.

Co-authorship network of co-authors of Sudeep Kundu

This figure shows the co-authorship network connecting the top 25 collaborators of Sudeep Kundu. A scholar is included among the top collaborators of Sudeep Kundu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sudeep Kundu. Sudeep Kundu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Strober, Bruce, Diamant Thaçi, Howard Sofen, et al.. (2023). Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary. Immunotherapy. 15(11). 787–797. 2 indexed citations

Armstrong, April W., Melinda Gooderham, Richard B. Warren, et al.. (2023). Treatment of Plaque Psoriasis with Deucravacitinib (POETYK PSO-1 Study): A Plain Language Summary. Immunotherapy. 15(12). 885–895. 2 indexed citations

Armstrong, April W., Melinda Gooderham, Richard B. Warren, et al.. (2022). Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. Journal of the American Academy of Dermatology. 88(1). 29–39. 219 indexed citations breakdown →

Strober, Bruce, Diamant Thaçi, Howard Sofen, et al.. (2022). Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. Journal of the American Academy of Dermatology. 88(1). 40–51. 173 indexed citations breakdown →

Strober, Bruce, Alice B. Gottlieb, Diamant Thaçi, et al.. (2020). An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis. SKIN The Journal of Cutaneous Medicine. 4(6). s73–s73. 1 indexed citations

Catlett, Ian M., Miroslawa Nowak, Sudeep Kundu, et al.. (2020). Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS‐986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo‐controlled trial in healthy participants. British Journal of Clinical Pharmacology. 86(9). 1849–1859. 19 indexed citations

Gordon, Kenneth B., Kim Papp, Melinda Gooderham, et al.. (2019). FRI0435 INFLUENCE OF BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS ON EFFICACY OF AN ORAL, SELECTIVE TYK2 INHIBITOR, BMS-986165, IN PATIENTS WITH PLAQUE PSORIASIS IN A PHASE 2 TRIAL. Annals of the Rheumatic Diseases. 78. 907–908. 2 indexed citations

Papp, Kim, Kenneth B. Gordon, Diamant Thaçi, et al.. (2018). Efficacy and Safety of a Potent and Highly Selective Oral Tyrosine Kinase 2 Inhibitor, BMS-986165, in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase II, Randomized, Placebo-Controlled Trial. Arthritis & Rheumatism. 70. 1 indexed citations

Papp, Kim, Kenneth B. Gordon, Diamant Thaçi, et al.. (2018). Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. New England Journal of Medicine. 379(14). 1313–1321. 289 indexed citations

10.

Sanyal, Arun J., Edgar D. Charles, Brent A. Neuschwander‐Tetri, et al.. (2018). Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. The Lancet. 392(10165). 2705–2717. 424 indexed citations breakdown →

11.

Charles, Edgar D., Brent A. Neuschwander‐Tetri, Juan P. Frías, et al.. (2018). Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study. Obesity. 27(1). 41–49. 210 indexed citations

12.

Zhou, Ming & Sudeep Kundu. (2016). Some practical considerations in three‐arm non‐inferiority trial design. Pharmaceutical Statistics. 15(6). 550–559. 2 indexed citations

13.

Lipworth, Brian J., Michael Kaliner, Craig LaForce, et al.. (2005). Effect of ciclesonide and fluticasone on hypothalamicpituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Annals of Allergy Asthma & Immunology. 94(4). 465–472. 91 indexed citations

14.

Szefler, Stanley J., Shashank Rohatagi, J. E. Williams, et al.. (2005). Ciclesonide, a Novel Inhaled Steroid, Does Not Affect Hypothalamic-Pituitary-Adrenal Axis Function in Patients With Moderate-to-Severe Persistent Asthma. CHEST Journal. 128(3). 1104–1114. 68 indexed citations

15.

Georgitis, John W., Stanley P. Galant, Mark Lloyd, et al.. (2004). ONCE-DAILY CICLESONIDE DOES NOT CAUSE HPA-AXIS SUPPRESSION IN PEDIATRIC ASTHMA PATIENTS. Pediatric Critical Care Medicine. 5(5). 511–511. 1 indexed citations

16.

Leff, Jonathan A., William W. Busse, David S. Pearlman, et al.. (1999). Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced Bronchoconstriction. Survey of Anesthesiology. 43(3). 185–186. 40 indexed citations

17.

Leff, Jonathan A., David S. Pearlman, Edwin A. Bronsky, et al.. (1998). Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced Bronchoconstriction. New England Journal of Medicine. 339(3). 147–152. 424 indexed citations

18.

Lepeleire, Inge De, Theodore F. Reiss, F Rochette, et al.. (1997). Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma*. Clinical Pharmacology & Therapeutics. 61(1). 83–92. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact